42237-85-4

Basic information

• Product Name: 3-AMINO-5-BROMOBENZOIC ACID
• Synonyms: Benzoicacid,3-aMino-5-broMo-;3-Amino-6-bromobenzoic acid
• CAS NO: 42237-85-4
• Molecular Formula: C₇H₆BrNO₂
• Molecular Weight: 216.04
• Product Categories: Aromatic Amino AcidsCarbonyl Compounds;C7;Carboxylic Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives;Aromatic Amino Acids;Building Blocks;Carbonyl Compounds;Carboxylic Acids;Chemical Biology;Chemical Synthesis;Organic Building Blocks;Peptide Chemistry;Unnatural Amino Acid Derivatives
• Mol File: 42237-85-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 217-221 °C
• Boiling Point: 342.4 °C at 760 mmHg
• Flash Point: 160.9 °C
• Appearance: /
• Density: 1.793
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.97±0.10(Predicted)
• CAS DataBase Reference: 3-AMINO-5-BROMOBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-BROMOBENZOIC ACID(42237-85-4)
• EPA Substance Registry System: 3-AMINO-5-BROMOBENZOIC ACID(42237-85-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 42237-85-4(Hazardous Substances Data)

Usage

General Description

3-Amino-5-bromobenzoic acid is a chemical compound with the molecular formula C7H6BrNO2. It is an organic compound with a benzene ring that has an amino group and a bromine atom attached to it. 3-Amino-5-bromobenzoic acid is commonly used in the production of pharmaceuticals, dyes, and organic synthesis. Its properties and structure make it valuable in medicinal chemistry research and drug development. 3-Amino-5-bromobenzoic acid has the potential to be a key building block for the synthesis of various biologically active compounds and can be utilized in the creation of new drugs and pharmaceuticals.

Upstream product

• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 78238-11-6 3-bromo-5-acetylaminobenzoic acid 
• 121-92-6 3-nitrobenzoic acid 
• 5326-49-8 N-(3-bromo-5-methylphenyl)acetamide 

Downstream Products

• 1374868-46-8 3-amino-5-cyclopentylbenzoic acid 
• 1445878-64-7 3-cyclopentyl-5-((7-(2,4-dimethoxypyrimidin-5-yl)-3-(N-isopropylsulfamoyl)quinolin-4-yl)amino)benzoic acid 
• 1445878-65-8 3-cyclopentyl-5-((7-(2,4-dimethoxypyrimidin-5-yl)-3-(N-propylsulfamoyl)quinolin-4-yl)amino)benzoic acid 
• 1445879-85-5 3-({7-bromo-3-[(propylamino)sulfonyl]-4-quinolinyl}amino)-5-cyclopentylbenzoic acid 
• 1445878-67-0 3-((3-(N-benzylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)-5-cyclopentylbenzoic acid 
• 1445879-88-8 3-[(7-bromo-3-{[(phenylmethyl)amino]sulfonyl}-4-quinolinyl)amino]-5-cyclopentylbenzoic acid 
• 1445879-56-0 5-((3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)-5'-oxo-2',3',4',5'-tetrahvdro[1,1'-biphenyl]-3-carboxylic acid 
• 1445878-68-1 3-cyclopentyl-5-((3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)benzoic acid 
• 1445879-90-2 3-({7-bromo-3-[(cyclopropylamino)sulfonyl]-4-quinolinyl}amino)-5-cyclopentylbenzoic acid 
• 1445879-66-2 3-((3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)-5-(3-oxocyclohexyl)benzoic acid 
• 1445880-70-5 3-amino-5-(3-oxocyclohexyl)benzoic acid 
• 1445879-93-5 3-{[7-bromo-3-(1-pyrrolidinylsulfonyl)-4-quinolinyl]amino}-5-cyclopentylbenzoic acid 
• 1445878-70-5 3-cyclopentyl-5-((7-(2,4-dimethoxypyrimidin-5-yl)-3-(pyrrolidin-1-ylsulfonyl)quinolin-4-yl)amino)benzoic acid 
• 1445878-73-8 3-{[3-(cyclohexylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino}-5-cyclopentylbenzoic acid 

Relevant articles and documents

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors

New (3-oxo)pyridazin-4-ylurea derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).